499 related articles for article (PubMed ID: 23227460)
1. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?
Bantis A; Grammaticos P
Hell J Nucl Med; 2012; 15(3):241-6. PubMed ID: 23227460
[TBL] [Abstract][Full Text] [Related]
2. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
3. Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients.
Zissimopoulos A; Bantis A; Stellos K; Petrakis G; Matthaios D
J BUON; 2008; 13(1):69-74. PubMed ID: 18404790
[TBL] [Abstract][Full Text] [Related]
4. Using prostate-specific antigen to eliminate the staging radionuclide bone scan.
Lee CT; Oesterling JE
Urol Clin North Am; 1997 May; 24(2):389-94. PubMed ID: 9126236
[TBL] [Abstract][Full Text] [Related]
5. Is bone scintigraphy necessary in initial staging of prostate cancer patients?
Jaukovic L; Adjinovic B; Cerovic S; Joksimovic M; Soldatovic Z
Hell J Nucl Med; 2011; 14(2):126-30. PubMed ID: 21761013
[TBL] [Abstract][Full Text] [Related]
6. [Role of rectal exploration, suprapubic and transrectal prostatic ultrasonography, and PSA in the diagnosis and follow-up of prostatic carcinoma].
Speranza I; Bianco V; Banci M; Muià R; Gianni W; Bacciu O; Vecchione A; Marchei P
Minerva Med; 1998; 89(7-8):267-75. PubMed ID: 9824988
[TBL] [Abstract][Full Text] [Related]
7. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate.
Bruwer G; Heyns CF; Allen FJ
Eur Urol; 1999; 35(3):223-7. PubMed ID: 10072624
[TBL] [Abstract][Full Text] [Related]
8. Cross-correlation of serum chromogranin A, %-F-PSA and bone scans in prostate cancer diagnosis.
Ahel MZ; Kovacic K; Tarle M
Anticancer Res; 2001; 21(2B):1363-6. PubMed ID: 11396214
[TBL] [Abstract][Full Text] [Related]
9. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
10. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
[TBL] [Abstract][Full Text] [Related]
11. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.
Huncharek M; Muscat J
Cancer Invest; 1995; 13(1):31-5. PubMed ID: 7530590
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
Aus G
Scand J Urol Nephrol Suppl; 1994; 167():1-41. PubMed ID: 7542397
[TBL] [Abstract][Full Text] [Related]
13. Follow-up in prostate cancer patients: which parameters are necessary?
Strohmaier WL; Keller T; Bichler KH
Eur Urol; 1999 Jan; 35(1):21-5. PubMed ID: 9933790
[TBL] [Abstract][Full Text] [Related]
14. Four prognostic indices in advanced prostate cancer patients, under palliative androgen deprivation treatment.
Bantis A; Zissimopoulos A; Kalaitzis C; Giannakopoulos S; Sountoulides P; Parmenopoulou V; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2008; 11(1):21-5. PubMed ID: 18392222
[TBL] [Abstract][Full Text] [Related]
15. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R
J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
[TBL] [Abstract][Full Text] [Related]
17. [The digital rectal exam, prostate-specific antigen and transrectal echography in the diagnosis of prostatic cancer].
Martínez de Hurtado J; Chéchile Toniolo G; Villavicencio Mavrich H
Arch Esp Urol; 1995 Apr; 48(3):247-59. PubMed ID: 7538749
[TBL] [Abstract][Full Text] [Related]
18. [Status of PSA determination for early detection of prostate carcinoma].
Hammerer P; Huland H
Versicherungsmedizin; 1995 Jun; 47(3):83-6. PubMed ID: 7541925
[TBL] [Abstract][Full Text] [Related]
19. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.
Briganti A; Passoni N; Ferrari M; Capitanio U; Suardi N; Gallina A; Da Pozzo LF; Picchio M; Di Girolamo V; Salonia A; Gianolli L; Messa C; Rigatti P; Montorsi F
Eur Urol; 2010 Apr; 57(4):551-8. PubMed ID: 20034730
[TBL] [Abstract][Full Text] [Related]
20. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer.
Huncharek M; Muscat J
Abdom Imaging; 1996; 21(4):364-7. PubMed ID: 8661585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
